| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
N/A |
| Shares
Out: |
26,519,000 |
| Market
Cap: |
18.78(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.55 - $1.72 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VolitionRx is an epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of life-altering diseases including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. Co.'s tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Co. is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,000 |
200,422 |
928,911 |
| Total Buy Value |
$0 |
$8,300 |
$194,762 |
$1,588,869 |
| Total People Bought |
0 |
1 |
11 |
12 |
| Total Buy Transactions |
0 |
1 |
20 |
37 |
| Total Shares Sold |
0 |
20,000 |
40,000 |
40,000 |
| Total Sell Value |
$0 |
$18,000 |
$33,000 |
$33,000 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
2 |
2 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skaff Habib |
Director |
– • – |
2016-05-20 |
4 |
OE |
$3.00 |
$12,000 |
D/D |
4,000 |
18,580 |
|
- |
|
| Rootsaert Rodney Gerard |
Secretary |
• – – |
2016-05-20 |
4 |
D |
$3.54 |
$30,002 |
D/D |
(8,475) |
1,525 |
|
- |
|
| Rootsaert Rodney Gerard |
Secretary |
• – – |
2016-05-20 |
4 |
OE |
$3.00 |
$30,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Innes Guy Archibald |
Director |
– • – |
2016-05-20 |
4 |
D |
$3.54 |
$15,003 |
D/D |
(4,238) |
1,228,503 |
|
- |
|
| Innes Guy Archibald |
Director |
– • – |
2016-05-20 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
1,232,741 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-05-20 |
4 |
S |
$3.54 |
$12,001 |
I/I |
(3,390) |
28,897 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-05-20 |
4 |
OE |
$3.00 |
$12,000 |
I/I |
4,000 |
32,287 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-05-20 |
4 |
D |
$3.54 |
$60,003 |
D/D |
(16,950) |
1,108,066 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-05-20 |
4 |
OE |
$3.00 |
$60,000 |
D/D |
20,000 |
1,125,016 |
|
- |
|
| Colman Alan |
Director |
– • – |
2016-05-20 |
4 |
D |
$3.54 |
$15,003 |
D/D |
(4,238) |
154,699 |
|
- |
|
| Colman Alan |
Director |
– • – |
2016-05-20 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
158,937 |
|
- |
|
| Micallef Jacob Vincent |
Chief Scientific Officer |
• – – |
2016-05-20 |
4 |
D |
$3.54 |
$60,003 |
I/I |
(16,950) |
31,506 |
|
- |
|
| Micallef Jacob Vincent |
Chief Scientific Officer |
• – – |
2016-05-20 |
4 |
OE |
$3.00 |
$60,000 |
I/I |
20,000 |
48,456 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-04-20 |
4/A |
OE |
$2.60 |
$3,047 |
D/D |
1,172 |
1,105,016 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-04-20 |
4 |
OE |
$2.60 |
$3,715 |
I/I |
1,429 |
28,287 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • – |
2016-04-20 |
4 |
OE |
$2.60 |
$3,047 |
D/D |
1,172 |
1,103,844 |
|
- |
|
| Colman Alan |
Director |
– • – |
2016-03-29 |
4 |
OE |
$0.50 |
$50,000 |
D/D |
100,000 |
153,937 |
|
- |
|
| Innes Guy Archibald |
Director |
– • – |
2016-03-22 |
4 |
OE |
$0.50 |
$50,000 |
D/D |
100,000 |
1,270,197 |
|
- |
|
| Terrell Jason Bradley Md |
Chief Medical OfficerOfficer |
• – – |
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
61,364 |
|
- |
|
| Faulkes Martin Charles |
Director |
– • – |
2015-12-14 |
4 |
OE |
$1.05 |
$262,500 |
D/D |
250,000 |
1,291,067 |
|
- |
|
| Micallef Jacob Vincent |
Chief Scientific Officer |
• – – |
2015-12-09 |
4 |
D |
$4.20 |
$150,503 |
I/I |
(35,834) |
28,456 |
|
- |
|
| Micallef Jacob Vincent |
Chief Scientific Officer |
• – – |
2015-12-09 |
4 |
OE |
$3.01 |
$150,500 |
I/I |
50,000 |
64,290 |
|
- |
|
| Micallef Jacob Vincent |
Chief Scientific OfficerOffice |
• – – |
2015-08-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
14,290 |
|
- |
|
| Micallef Jacob Vincent |
Chief Scientific OfficerOffice |
• – – |
2015-08-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
86,166 |
|
- |
|
| Reynolds Cameron John |
President and CEO |
• • • |
2015-05-15 |
4 |
B |
$3.32 |
$4,989 |
D/D |
1,500 |
1,103,844 |
3.15 |
- |
|
321 Records found
|
|
Page 12 of 13 |
|
|
0.03 (4.89%) 
